– LONDON, October 20, 2015 /PRNewswire/ —
Norgine B.V today announced that it will be presenting the following key data;
     (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )
1. European Colonoscopy Quality Investigation Group: Improving Standards in Colonoscopy Through a Practice Level Audit Tool. Abstract: UEG15-ABS-3692 
2. New Low-Volume Bowel Cleansing Solution (NER1006) vs Trisulphate, Polyethylene Glycol 3350+Ascorbate or Sodium Picosulphate/Magnesium Salt: Three Ongoing Multicentre Randomised Parallel Group Phase III Studies in 1914 Patients Undergoing Colonoscopy. Abstract: 15-ABS-3387 
3. Impact of Switching From a Brand to a Generic Macrogol on Prescriptions and Doses for Patients with Chronic Constipation in the UK. Abstract: UEG15-ABS-2167 
4. Cost Effectiveness of Rifaximin-α 550 mg (XIFAXAN/TARGAXAN) in the Reduction of Recurrence of Overt Hepatic Encephalopathy in United Kingdom. Abstract: UEG15-ABS-1973 
5. Cost Effectiveness of Rifaximin-α 550 mg (XIFAXAN/TARGAXAN) in the Reduction of Recurrence of Overt Hepatic Encephalopathy in Sweden. Abstract: UEG15-ABS-1961 
See full release on http://www.norgine.com
Contact:
Isabelle Jouin, T: +44(0)1895-453643
Charlotte Andrews, T: +44(0)1895-453607
Follow us @norgine